Heart Rate Variability, Vagus Nerve and Cancer

Last updated: May 10, 2024
Sponsor: Centre Hospitalier Henri Duffaut - Avignon
Overall Status: Terminated

Phase

N/A

Condition

Cancer

Colon Cancer

Bone Neoplasm

Treatment

Osteopathic intervention

QLQ-C30 questionnaire

CRP assessment

Clinical Study ID

NCT04718610
OSTEOCAN
  • Ages > 18
  • All Genders

Study Summary

In France, new cancer cases keep on increasing with around 150 000 deaths yearly. Cancer therapy research is constantly evolving. Indeed, several studies explore new treatments or their combination with conventional cancer treatments. But, at the same time, complementary and alternative medicines, as osteopathy, remain little explored upon their role in the combination with conventional therapy.

Several studies showed indirect interaction between vagus nerve and cancer. Firstly, vagus nerve regulates homeostasis and immunity by reducing systemic inflammation while maintaining local inflammation and antitumor effects. Secondly, vagus nerve stimulation increases Heart Rate Variability (HRV). Moreover, a higher HRV is associated with an improvement of vital prognosis in cancer patients. Vagus nerve could be stimulated by noninvasive osteopathic manipulations.

This prospective, monocentric and randomized study is a collaboration between the Centre Hospitalier d'Avignon and the Institut de Formation en Ostéopathie du Grand Avignon. It focuses on using noninvasive osteopathic mobilizations to stimulate vagus nerve. Indeed, this study aims to evaluate effects of vagus nerve osteopathic stimulations on HRV in patients with lung cancer, colorectal cancer, Non Hodgkin Lymphoma or Multiple Myeloma. More specifically, this study will tell us whether vagus nerve noninvasive osteopathic stimulations induce increase of HRV associated with a decrease of systemic inflammation and an improvement of patient's quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with lung cancer or colorectal cancer or Non Hodgkin Lymphoma or MultipleMyeloma (Stade I à IV)

  • No previous treatment

  • HRV < 70 ms

  • No osteopathic contraindication

Exclusion

Exclusion Criteria:

  • Vagotomy

  • Heart arrhythmia

  • Cancer recurrence

  • Consumption of coffee or tabac within 2 hours prior osteopathic treatment

  • Consumption of alcohol within 24 hours prior osteopathic treatment

Study Design

Total Participants: 25
Treatment Group(s): 3
Primary Treatment: Osteopathic intervention
Phase:
Study Start date:
January 12, 2021
Estimated Completion Date:
September 19, 2021

Connect with a study center

  • Centre Hospitalier Henri Duffaut

    Avignon, 84000
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.